How may we assist you?

  • Pepscan grants Bicycle Therapeutics a global CLIPS Technology license for product candidates BT1718 and THR- 149

    Lelystad, the Netherlands – November 20th 2020 – Pepscan, the all-in-one peptide service provider with proprietary peptide constraining technologies, today announced that it has entered into a global agreement with Bicycle Therapeutics plc regarding the use of Pepscan’s CLIPS peptide technology for the further development of Bicycle’s product candidates BT1718 and THR-149. As expert in constrained peptides, Pepscan developed a proprietary, highly versatile constraining technology to lock peptides into active conformations, called CLIPS (Chemical Linkage of Peptides onto Scaffolds). The …

  • Passion for peptides – The people behind Pepscan

    “The therapeutic peptide pipeline under one roof” Pepscan’s team of around 40 entrepreneurial, specialized scientists focus their daily work on enabling breakthroughs in life sciences. Eline Fijlstra joined Pepscan in 2017 as one of the technicians in the epitope mapping group. She is now a technician and analyst in the peptide discovery group. “After finishing my Bachelor’s in Biology and Medical Laboratory Research at HAN University of Applied Sciences, I found at Pepscan’s planned peptide discovery group the perfect place …

  • Flexibility – A combination of skills and facilities

    In addition to a team of highly skilled specialists in smart peptide science, our flexible manufacturing capabilities are key to how we support our customers. Flexibility not only allows us to reliably deliver personalized peptides for neoantigen vaccines in very short timelines, but it also gives us the ability to quickly ramp up or make room for additional clinical or R&D orders in our synthesis pipeline. Lean Six Sigma Yellow Belt As part of Pepscan’s training program, a group of …

  • Pepscan lance son site internet en français

    Pepscan lance aujourd’hui la version française de son site internet et salue chaleureusement tous ses visiteurs francophones. Nous répondons ainsi à la demande croissante des visiteurs francophones sur notre site internet et nous présentons désormais de façon accessible notre expertise en matière de peptides, nos produits complexes et notre technologie. Notre site internet nous permet également de partager des informations sur les bénéfices que leur exploitation apporte à la communauté scientifique. « Alors que la science des peptides est majoritairement anglophone, …

  • French version of Pepscan website launched

    To accommodate the growing numbers of French speakers visiting our website, Pepscan has launched a French version. Our website not only serves to inform visitors about Pepscan’s offering, but also is a tool for sharing knowledge around our technologies and the benefits they bring to the scientific community. “Although peptide science – and as a result Pepscan – is a highly international and English-focused field, we want to welcome French speaking scientists in their own language. This approach fits with …

  • Passion for peptides – The people behind Pepscan

    “I’m convinced that collaboration and sharing knowledge are key in supporting our clients to be successful in the clinics.” The market for personalized neoantigen peptide cancer vaccines is very young. Currently there are about 20-30 clinical trials running worldwide and one of the first Phase I trials finished recently. Results for this new approach of cancer treatment are very promising and more studies are started up at a quick rate. Pepscan, as the manufacturer of neoantigen peptides and working with …

  • Epitope mapping – Instrumental in therapeutic antibody development

    Recently, we launched a worldwide campaign to stress the importance of epitope mapping in therapeutic antibody development. Part of this campaign is a movie featuring Dr. Dennis Flierman (Director Epitope Mapping) and Dr. Marty Wulferink (European and Dutch patent attorney). Epitope mapping not only plays a key role in functional understanding and selection of antibodies, but also in IP protection and FDA/EMA approval. Recent patent disputes have illustrated the necessity of epitope mapping in protecting a company’s interests. It is …

  • Webinar Peptide Discovery: the power of CLIPS™

    Therapeutic peptides are becoming increasingly important within the pharma industry and currently represent a market value of 28 billion USD with an annual growth rate of at least 10% over the next five years. Pepscan has developed a unique technology to discover new highly constrained peptides with enhanced affinity, selectivity and proteolytic stability suited for diagnostic and therapeutic applications. Phage display is a technology that allows for the de novo discovery of peptides against any target of interest by exploring …

  • “Pepscan has been the reliable expert partner for us with the right capacities to start our clinical journey”

    Annually thousands of pharma and biotech companies launch a clinical trial to evaluate the efficacy and safety of their potential new therapeutic or diagnostic tool. BiOrion is one of the companies that will take its first step in this clinical trajectory this year with their targeted peptide treating fibrotic diseases. Getting ready for the clinic “It is very exciting being able to enter the clinic. Therefore, we were looking for a reliable expert partner who is able to manufacture our …

  • COVID-19 Services – Patient sera epitope mapping as a tool in COVID-19 vaccine development

    Pepscan’s Precision Epitope Mapping Platform provides scientists the ability to identify the best peptide leads from large collections of patient sera and to pinpoint strain-specific or region-specific differences in immune responses. This platform is one of the tools in the search for a COVID-19 vaccine to subdue the current pandemic. “Using Pepscan’s CLIPS Precision Epitope Mapping Platform, we can screen patient and control samples to assess whether distinct epitopes are prevalent in patient sera. The addition of conformational peptide mapping …

We use cookies to ensure that we give you the best experience on our website. We also use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on the Pepscan website. However, if you would like to, you can change your cookie settings at any time in your browser.
Cookie Policy
Find out more
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Cookie Settings
Accept All Cookies